Clinical trial results:
Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)

Summary

EudraCT number	2010-021556-25
Trial protocol	IT
Global end of trial date	30 September 2013

Results information

Result version number	v1 (current)
This version publication date	21 March 2019
First version publication date	21 March 2019
Summary attachment (see zip file)	cervigni-2016 (cervigni-2016.pdf)

Trial information

Trial identification

Sponsor protocol code	IBSA 01-2010

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	IBSA Institut Biochimique SA
Sponsor organisation address	Via del Piano 29, Pambio-Noranco, Switzerland, 6915
Public contact	Valeria Frangione, IBSA Institut Biochimique SA, +41 583601000, valeria.frangione@ibsa.ch
Scientific contact	Valeria Frangione, IBSA Institut Biochimique SA, valeria.frangione@ibsa.ch

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 January 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 September 2013
Global end of trial reached?	Yes
Global end of trial date	30 September 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the study was the assessment of the efficacy of Ialuril as compared to DMSO (RIMSO-50) in patients suffering from BPS/IC

Protection of trial subjects:

No other intravesical drug was allowed throughout the study, either during the treatment or during the follow-up period.
No other restrictions in prior or concomitant therapy were considered in the protocol.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 June 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	3 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Italy: 110
Worldwide total number of subjects	110
EEA total number of subjects	110

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	91
From 65 to 84 years	18

85 years and over	1

Subject disposition

Recruitment

Recruitment details:

Italy
FPFV: 30-Jun-2011
LPLV: 30-Sep-2013

Pre-assignment

Screening details:

110 female patients older than 18 with diagnosis of BPS/IC were screened

Period 1

Period 1 title	Study Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Ialuril

Arm description:

intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment

Arm type	Experimental
Investigational medicinal product name	Ialuril
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Intravesical solution
Routes of administration	Intravesical use

Dosage and administration details:

intravesical instillation every 7 days for a total of 13 instillations over 3 months

Arm title	DMSO

Arm description:

intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment

Arm type	Active comparator
Investigational medicinal product name	RIMSO-50
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Intravesical solution
Routes of administration	Intravesical use

Dosage and administration details:

one instillation every 7 days for a total of 13 instillations, over 3 months

Number of subjects in period 1	Ialuril	DMSO
Started	74	36
Completed	59	29
Not completed	15	7
Consent withdrawn by subject	5	3
Adverse event, non-fatal	1	2
Lost to follow-up	6	-
Lack of efficacy	2	2
Protocol deviation	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Ialuril
Reporting group description:	
intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment	
Reporting group title	DMSO
Reporting group description:	
intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment	

Reporting group values	Ialuril	DMSO	Total
Number of subjects	74	36	110
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	50.95	48.78	
standard deviation	± 14.97	± 17.70	-
Gender categorical			
Units: Subjects			
Female	74	36	110
Male	0	0	0

End points

End points reporting groups

Reporting group title	Ialuril
Reporting group description: intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment	
Reporting group title	DMSO
Reporting group description: intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment	

Primary: VAS pain reduction

End point title	VAS pain reduction
End point description:	
End point type	Primary
End point timeframe: at 6 months (end of follow-up) versus baseline	

End point values	Ialuril	DMSO		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74	36		
Units: mm				
arithmetic mean (standard deviation)	39.15 (± 29.14)	30.36 (± 30.53)		

Statistical analyses

Statistical analysis title	Primary Endpoint
Statistical analysis description: Difference Ialuril vs. RIMSO-50 in VAS pain reduction	
Comparison groups	DMSO v Ialuril
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.111 [1]
Method	ANCOVA

Notes:

[1] - between treatment groups

Adverse events

Adverse events information

Timeframe for reporting adverse events:

The study was divided into 3 periods: screening (Visit 1), treatment (13 weekly visits), follow-up (Visit 15 after 3 months without any treatment). Adverse Events were evaluated at each visit.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	16.1

Reporting groups

Reporting group title	Ialuril

Reporting group description:

intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment

Reporting group title	DMSO

Reporting group description:

intravesical instillation every 7 days for a total of 13 instillations over 3 months + 3 months of follow-up without treatment

Serious adverse events	Ialuril	DMSO	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 74 (0.00%)	0 / 36 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Ialuril	DMSO	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 74 (1.35%)	8 / 36 (22.22%)	
Renal and urinary disorders			
Bladder pain			
subjects affected / exposed	1 / 74 (1.35%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Bladder irritation			
subjects affected / exposed	0 / 74 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Cystitis			

subjects affected / exposed	0 / 74 (0.00%)	2 / 36 (5.56%)	
occurrences (all)	0	4	
Dysuria			
subjects affected / exposed	0 / 74 (0.00%)	4 / 36 (11.11%)	
occurrences (all)	0	4	
Strangury			
subjects affected / exposed	0 / 74 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 January 2012	Urodynamic test, Cystourethroscopy and Vulvoscopy were considered as "Optional" at screening and during the study. Some inclusion criteria were better specified and, in particular: - criterion n. 2 was changed to reflect the ESSIC guideline nomenclature, as for what regards the disease under study (from "IC/PBS" to "BPS/IC") - criterion n. 4 was changed to allow the recruitment of patients who are not sexually active.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/27654012